
IDEX (IEX) Stock Forecast & Price Target
IDEX (IEX) Analyst Ratings
Bulls say
IDEX has generated $3.3 billion in revenue for 2024, showcasing a robust financial performance within its diversified business segments. The company possesses a well-established portfolio of highly-engineered solutions that are expected to grow at rates exceeding underlying GDP over economic cycles, supported by pricing power. Despite mixed end market conditions, including strengths in various sectors such as pharmaceuticals and stable OEM demand, IDEX’s strategic position underscores its potential for sustained growth.
Bears say
IDEX's financial outlook appears negative due to ongoing mixed organic sales and order trends across its three business segments, prompting a reduction in the core revenue growth forecast for 2026. Furthermore, while balance sheet net leverage showed a slight sequential decrease from 1.5x to 1.4x, the company anticipates flat to low single-digit declines in volume this year, which could compress earnings per share (EPS). Additionally, IDEX's gross debt/EBITDA ratio stands at 2.1x, reflecting a continued need for careful management of leverage amid challenging market conditions.
This aggregate rating is based on analysts' research of IDEX and is not a guaranteed prediction by Public.com or investment advice.
IDEX (IEX) Analyst Forecast & Price Prediction
Start investing in IDEX (IEX)
Order type
Buy in
Order amount
Est. shares
0 shares